Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
about
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsHigh-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient dataHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsSurvival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOPThe use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review.Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.NHL (diffuse large B cell lymphoma)Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.NHL (diffuse large B-cell lymphoma).Adverse events associated with chemotherapy for common cancers.Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphomaWhy aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?Current trends in large cell lymphoma.Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study.Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario.Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma.A six-drug regimen (MAPECO) for intermediate or high-grade non-Hodgkin's lymphoma.Bone marrow transplantation in low-grade non-Hodgkin's lymphoma.Autologous stem cell transplants in lymphomas.Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma.Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.Incidence and survival of gastric non-Hodgkin's lymphoma: a population-based study from the Association of the French Cancer Registries (FRANCIM).
P2860
Q24242089-199C03B8-B65E-47FD-94E3-865A49659BFFQ24242447-15B5F1FF-737D-4BC8-A2EB-E5D4F64F670AQ24250490-28E49377-647C-4359-878C-6DE7D1862BF3Q28346778-68B7E1B0-2360-43FD-8554-220208F648EAQ30845199-62B216A8-C93D-46A4-9E93-15A5607D1B80Q33344965-00663B07-0D5C-4228-8EDC-8E5996162C53Q33375173-1D3E9DB6-C919-4B38-9672-8714A49E3F5BQ33396036-5BFA1D73-3F8F-41D3-B7EC-2A55D06D01B4Q33396261-5601F855-032A-4314-8685-5156A4233E69Q33446735-6CDB7F03-9436-4926-8844-8EBF3EED1846Q33629525-0CBE6BE4-9A59-4B8A-A13E-730BB6012CB5Q33710715-A40F2C30-5FA9-4CDA-9692-30FAA82CE3F1Q33846734-89E0DC3F-BC8A-4F83-B2A7-301B15318201Q33975228-FF4AE14E-F9CD-43A2-944E-D2F09CAC40ECQ35004750-A6C691BD-3F98-4991-A1E2-C17DA2227987Q35084382-FE1D4408-B0E7-4ADF-B22C-E1C289E904D7Q35139841-4A35CC34-0172-46A2-BF45-5692AC64CEF3Q35545076-9F96056C-A960-440A-A760-A18CB8973C97Q35992515-329FA833-3BEB-47EE-9DCD-0BA14E6CF8ACQ36080167-3F35B60B-1B42-4B44-810D-3EC932724106Q36292887-AF5EC604-1880-4FF8-9308-AA4F01CEE8F1Q36416332-7087DFEC-A227-40C4-9524-0B8B80E7BCABQ37164915-AC12699E-C26C-40EB-8725-E1AF99F248C8Q37411182-BC8ABAEB-6733-4CEA-9A69-06368B2E429FQ37428422-3206A0B2-8C3B-4488-A930-1D9C57D1F4FDQ40394117-0B9C8A85-BF16-425C-A2F1-ADB56B7A4C83Q40691025-071AF2F3-C6BA-43F6-872E-3EF675AEC33CQ40708078-3E464C32-F199-4EA0-8F15-62916497EF0CQ40958067-9504E822-AF51-4946-966A-B866AE88BB04Q41056685-F9606E27-E97B-4D57-9407-7D680C76648FQ43196809-C943A687-D416-4AC0-99BE-4251481EDB7DQ43653702-34CFEEAC-325D-4F04-ABED-7099D5C6FBD9Q43822769-07FF91EB-77F3-42D9-BF75-DCECAD521D37Q44030861-113D862D-52BD-4A80-AAA1-F5B72A28745EQ44397242-53FE0824-3BB6-48D6-BB1F-B0231182DE22Q44455479-CBA5583E-76B2-4A04-96CC-AE0F05CBEC10Q44468092-97BD936C-E73F-4CE0-8C1E-947C4C3732E9Q44859839-BCC649D3-FECE-408A-991C-3FD2F2F4B3DCQ45204161-50DB9C60-294C-4CF9-B355-706CE83B51ABQ45215407-EB4C696E-E422-473A-A82E-345150BF7AC2
P2860
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@ast
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@en
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@nl
type
label
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@ast
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@en
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@nl
prefLabel
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@ast
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@en
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@nl
P2093
P1476
Comparison of a second-generat ...... diffuse non-Hodgkin's lymphoma
@en
P2093
A Gottlieb
D Harrington
G D Resnick
J Andersen
L I Gordon
P304
P356
10.1056/NEJM199211053271903
P407
P577
1992-11-05T00:00:00Z